Hostname: page-component-669899f699-ggqkh Total loading time: 0 Render date: 2025-04-27T19:02:14.670Z Has data issue: false hasContentIssue false
  • English
  • Français

Genetics of Platelet MAO Activity in Discordant Schizophrenic and Normal Twins

Published online by Cambridge University Press:  29 January 2018

Michael A. Reveley ,
Adrianne M. Reveley ,
Christine A. Clifford  and
Robin M. Murray
Michael A. Reveley
Affiliation:
Genetics Section, Institute of Psychiatry, De Crespigny Park, London SE5 8AF
Adrianne M. Reveley
Affiliation:
Genetics Section, Institute of Psychiatry, De Crespigny Park, London SE5 8AF
Christine A. Clifford
Affiliation:
Genetics Section, Institute of Psychiatry, De Crespigny Park, London SE5 8AF
Robin M. Murray
Affiliation:
Genetics Section, Institute of Psychiatry, De Crespigny Park, London SE5 8AF
Get access Rights & Permissions [Opens in a new window]

Summary

Platelet monoamine oxidase (MAO) activity was compared in four age and sex-matched groups: monozygotic (MZ) twins discordant for schizophrenia, normal MZ twins, normal dizygotic (DZ) twins and unrelated individuals. Among the twin groups, schizophrenic and normal, there was a remarkably consistent degree of genetic control amounting to 70–80 per cent of the variation in activity. The mean platelet MAO activity of the schizophrenic twins was significantly lower than that of controls, but not than that of their psychiatrically well, neuroleptic-free cotwins; indeed the correlation for the MZ twins discordant for schizophrenia was almost exactly the same as that for the normal MZs. Thus, lower platelet MAO activity in schizophrenia, where it is found, is genetically modulated and not the result of the illness or its treatment.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 142 , Issue 6 , June 1983 , pp. 560 - 565
Copyright
Copyright © 1983 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Baron, M. & Levitt, M. (1980) Platelet monoamine oxidase activity: relation to genetic load of schizophrenia. Psychiatry Research, 3, 69–74.Google Scholar
Belmaker, R. H., Galon, A., Perez, L. & Ebstein, R. (1977) Platelet MAO in schizophrenics with and without a family history of schizophrenia. British Journal of Psychiatry, 131, 551–2.Google Scholar
Berrettini, W. H., Benfield, T. C., Schmidt, A. O., Ladman, R. K. & Vogel, W. H. (1980) Platelet monoamine oxidase in families of chronic schizophrenics. Schizophrenia Bulletin, 6, 235–7.CrossRefGoogle ScholarPubMed
Böök, J. A., Wetterberg, L. & Modrzewska, K. (1978) Schizophrenia in a North Swedish geographical isolate, 1900–1977. Epidemiology, genetics and biochemistry. Clinical Genetics, 14, 373–94.Google Scholar
Buchsbaum, M. S., Coursey, R. D. & Murphy, D. L. (1976) The biochemical high-risk paradigm: behavioural and familial correlates of low platelet monoamine oxidase activity. Science, 194, 339–41.CrossRefGoogle ScholarPubMed
Chojnacki, M., Kralik, P., Allen, R. H., Ho, B. T., Schoolar, J. C. & Smith, R. C. (1981) Neuroleptic-induced decrease in platelet MAO activity of schizophrenic patients. American Journal of Psychiatry, 138, 838–40.Google ScholarPubMed
De Lisi, L. E., Wise, C. D., Bridge, T. P., Rosenblatt, J. E., Wagner, R. L., Morihisa, J., Karson, C., Potkin, S. G. & Wyatt, R. J. (1981) A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients. Psychiatry Research, 4, 95–107.CrossRefGoogle ScholarPubMed
Donnelly, C. H. & Murphy, D. L. (1977) Substrate and inhibitor related characteristics of human platelet monoamine oxidase. Biochemical Pharmacology, 26, 853–8.CrossRefGoogle ScholarPubMed
Emery, A. E. H. (1976) Methodology in Medical Genetics, pp. 85–87. Edinburgh: Churchill Livingstone.Google Scholar
Hussein, L., Sindarto, E. & Goedde, H. W. (1980) Twin studies and substrate differences in platelet monoamine oxidase activity. Human Heredity, 30, 65–70.CrossRefGoogle ScholarPubMed
Johnston, J. P. (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochemical Pharmacology, 17, 1285–97.CrossRefGoogle ScholarPubMed
Johnstone, E. C., Crow, T. J., Frith, C. D., Husband, J. & Kreel, L. (1976) Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet, 2, 924–6.Google ScholarPubMed
Koide, Y., Eberhard, G., Sääf, J., Ross, S. B., Wahlund, L-O. & Wetterberg, L. (1981a) Kinetic aspects of monoamine oxidase activity in twins with psychoses. Clinical Genetics, 19, 395–400.CrossRefGoogle ScholarPubMed
Koide, Y., Sääf, J., Wahlund, L-O., Ross, S. B. & Wetterberg, L., (1981b) Platelet monoamine oxidase activity in schizophrenic families—kinetic aspects. Clinical Genetics, 19, 405–9.Google Scholar
Kruk, Z. L., Moffett, A. & Scott, D. F. (1980) Platelet monoamine oxidase activity in epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 43, 68–70.Google Scholar
Mann, J. & Thomas, K. M. (1979) Platelet monoamine oxidase activity in schizophrenia. Relationship to disease, treatment, institutionalisation and outcome. British Journal of Psychiatry, 134, 366–71.CrossRefGoogle ScholarPubMed
Murphy, D. L., Belmaker, R. & Wyatt, R. J. (1974) Monoamine oxidase in schizophrenia and other behavioural disorders. Journal of Psychiatric Research, 11, 221–48.CrossRefGoogle Scholar
Murphy, D. L., Wright, C., Buchsbaum, M., Nichols, A., Costa, J. L. & Wyatt, R. J. (1976) Platelet and Plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochemical Medicine, 16, 254–65.Google Scholar
Murphy, D. L. & Wyatt, R. J. (1972) Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature, 238, 225–6.CrossRefGoogle ScholarPubMed
Nies, A., Robinson, D. S., Lam born, K. R. & Lampert, R. P. (1973) Genetic control of platelet and plasma monoamine oxidase activity. Archives of General Psychiatry, 28, 834–8.Google Scholar
Owen, F., Bourne, R., Crow, T. J., Johnstone, E. C., Bailey, A. R. & Hershon, H. I. (1976) Platelet monoamine oxidase in schizophrenia. Archives of General Psychiatry, 33, 1370–3.Google Scholar
Owen, F., Bourne, R., Crow, T. J., Fadhu, A. A. & Johnstone, E. C. (1981) Platelet monoamine oxidase activity in acute schizophrenia: relationship to symptomatology and neuroleptic medication. British Journal of Psychiatry, 139, 16–22.Google Scholar
Pandey, G. N., Dorus, E., Shaughnessy, R. & Davis, J. M. (1979) Genetic control of platelet monoamine oxidase activity: Studies on normal families. Life Sciences, 25, 1173–8.Google Scholar
Propping, P. & Friedl, W. (1979) Platelet monoamine oxidase activity in first degree relatives of schizophrenic patients. Psychopharmacology, 65, 265–72.Google Scholar
Reveley, A. M., Reveley, M. A. & Murray, R. M. (1981) Effects of neuroleptic drugs on MAO activity. British Journal of Psychiatry, 139, 475–6.Google Scholar
Reveley, A. M., Reveley, M. A., Clifford, C. A. & Murray, R. M. (1982) Cerebral ventricular size in twins discordant for schizophrenia. Lancet i, 540–1.Google Scholar
Reveley, M. A., Gurling, H. M. D., Glass, I., Glover, V. & Sandler, M. (1980) Platelet γ-aminobutyric acid—aminotransferase and monoamine oxidase in schizophrenia. Neuropharmacology, 19, 1249–50.Google Scholar
Sahai, S., Arora, R. & Meltzer, H. Y. (1981) Effect of chlorpromazine treatment on monoamine oxidase activity in platelets isolated by the Corash method. Psychiatry Research, 5, 111–4.Google Scholar
Sandler, M., Reveley, M. A. & Glover, V. (1981) Human platelet monoamine oxidase in health and disease: a review. Journal of Clinical Pathology, 34, 292–302.CrossRefGoogle ScholarPubMed
Spitzer, R. L. & Endicott, J. (1977) The Schedule for Affective Disorders and Schizophrenia, Lifetime Version, 3rd Edition. New York: New York State Psychiatric Institute.Google Scholar
Spitzer, R. L., Endicott, J. & Robins, E. (1975) Research Diagnostic Criteria, Instrument No. 58. New York: New York State Psychiatric Institute.Google Scholar
Weinberger, D. R., Torrey, E. F., Neophytides, A. N. & Wyatt, R. J. (1979) Lateral cerebral ventricular enlargement in chronic schizophrenia. Archives of General Psychiatry, 36, 735–9.Google Scholar
Winter, H., Herschel, M., Propping, P., Friedl, W. & Vogel, F. (1978) A twin study on three enzymes (DBH, COMT, MAO) of catecholamine metabolism: correlations with MMPI. Psychopharmacology, 57, 63–9.CrossRefGoogle ScholarPubMed
Wyatt, R. J., Murphy, D. L., Belmaker, R., Cohen, S., Donnelly, C. H. & Pollin, W. (1973) Reduced monoamine oxidase activity in platelets: a possible genetic marker for vulnerability to schizophrenia. Science, 179, 916–8.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.